Abbott Laboratories

New Capabilities

Sponsor of the TECTONIC CAD trial; expects FDA approval of SonicForce in the first half of 2027

Abbott's SonicForce met both of its primary endpoints in a 335-patient U.S. study of severely calcified coronary arteries. Thirty-day target lesion failure was 0.3% and procedural success was 97.0%, results presented Nov. 1 at the TCT conference in San Diego and published in JACC: Cardiovascular Interventions.

Updated 3 days ago

New Capabilities

Device authorized; US launch planned for later in 2026

The FDA on August 25 authorized Abbott's Libre Duo 10 Day, the first wearable that continuously tracks both blood sugar and ketone levels in one sensor. It reads fluid under the skin every minute for up to 10 days, for people as young as 2.

Updated 6 days ago

Money Moves

As of May 2026: Acquirer

Abbott Laboratories closed its $21 billion acquisition of Exact Sciences on March 23, making the maker of the Cologuard colorectal cancer screening test a wholly owned subsidiary of one of the world's largest healthcare companies. The all-cash deal, at $105 per share, passed through antitrust review without a second request from regulators—a sign of how little the two companies' product lines overlapped before this combination.

Updated May 30